

ADISCTI (Adis Clinical Trials Insight)

Subject Coverage

- Drugs and drug therapy
- Adverse drug reactions
- Pharmacoeconomics

File Type Bibliographic, Full text

Features

Thesaurus	None		
Alerts (SDIs)	Weekly		
CAS Registry Number [®] Identifiers	<input type="checkbox"/>	Page Images	<input type="checkbox"/>
Keep & Share	<input type="checkbox"/>	SLART	<input checked="" type="checkbox"/>
Learning Database	<input type="checkbox"/>	Structures	<input type="checkbox"/>

Record Content

- Bibliographic and indexing information
- Summaries contain side effects tables, ADIS comments, global study outcomes, purpose of the paper, author comments, drug tables listing dosage information, results tables.

File Size More than 175,600 records (08/19)

Coverage 1998-present, from more than 1,700 medical and biomedical publications.

Updates Weekly

Language English

Database Producer Springer International Publishing AG
Copyright Holder

Contact Springer Online Services support desk:
 Email: onlineservice@springer.com
 Phone: +49 6221 345 4303 (Europe/Asia/Africa)
 +1 800 777 4643 (North & South America)

SourcesAdis Clinical Trials Insight

User Aids

- Online Helps (HELP DIRECTORY lists all help messages available)
 - STNGUIDE
-

Cluster

- ADISBASES
- ALLBIB
- AUTHORS
- BIOSCIENCE
- CORPSOURCE
- FULLTEXT
- HEALTH
- MEDICINE
- PHARMACOLOGY
- TOXICOLOGY

STN Database Cluster information:

<http://www.stn-international.com/en/customersupport/customer-support#cluster+%7C+subjects+%7C+features>

Search and Display Field Codes

Fields that allow left truncation are indicated by an asterisk (*).

General Search Fields

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index * (contains single words from the title (TI), controlled term (CT), text (TX), and evaluation (EVAL) fields)	None (or /BI)	S PHARMACOKINETICS S QUALITY OF LIFE S RESIST? (L) NEGATIVE S VACCINE# (S) USE S PATIENT-CONTROLLED S ?DIABET(L)?THERAP?	CT, EVAL, TI, TX
Accession Number ADIS Last Update Date (2) ADIS Record Creation Date (2) Author	/AN /DUP /DED /AU	S 2006:1005/AN S 20051004/DUP S 20051004/DED S JENSEN P?/AU S JENSEN, P?/AU	AN DUP DED AU
Controlled Term	/CT	S THERAPEUTIC EQUIVALENCE/CT S CORONARY SPASM, TREATMENT/CT	CT
Controlled Word	/CW	S (ACICLOVIR (L) ACTIVITY)/CW S (INHIBITORS (S) ANTIMICROBIAL)/CW	CT
Corporate Source (organization name and location) (1) Document Number Document Type (text)	/CS /DN /DT (or /TC)	S (VETERANS AFFAIRS AND ALABAMA)/CS S 801032402/DN S BEST EVIDENCE/DT	CS DN DT
Entry Date (2) Evaluation (3,4)	/ED /EVAL	S L1 AND ED>=20051100 S CONTROLS/EVAL S MEDIA RELEASE/EVAL	ED EVAL
Field Availability International Standard (Document) Number Journal Title (contains full and abbreviated journal titles) Language (code and text)	/FA /ISN /JT /LA	S L3 AND SIDE/FA S 8750-2836/ISN S REGION ANESTH/JT S REGIONAL ANESTHESIA/JT S L2 AND ENGLISH/LA S L2 AND EN/LA	Not displayed ISN, SO JT, JTA, JTF, SO LA
Number of Patients (2,3) Ongoing Trial Comment Other Source	/PNO /OT /OS	S PNO<=100 S TRANSDERMAL?/OT S 2006000118/OS S ADISINSIGHT/OS	PNO OT OS
Publication Date (2) Publication Year (2) Reference (1) Source (contains journal title, publication date, ISSN, and collation information (volume, issue, and page numbers)) Title *	/PD /PY /RE /SO /TI	S JUN 1-30 2005/PD S 2004/PY S EPILEPSY DISORDERS/RE S (BIOLO? AND BULL? AND VOL 20)/SO S (VITRO AND ACTIVITY)/TI S ?MALARIA?/TI S (KETOLIDE (S) ANTIMICROBIAL)/TI	PD, SO PY, SO RE SO TI
Update Date (2) Word Count (2,3)	/UP /WC	S L7 AND 20021100-20021200/UP S L1 AND WC<200	ED WC

ADISCTI

- (1) Implied (S) proximity is available in this field.
 (2) Numeric search field that may be searched using numeric operators or ranges.
 (3) This field is available only in the SUMMARY file segment.
 (4) See HELP SCORE for more information.
 (5) This score is only available in selected records published in November 2010 and earlier.

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 TI AU. The fields are displayed or printed in the order requested.

Hit-term highlighting is available for all fields. Highlighting must be ON during SEARCH to use the HIT, KWIC, and OCC formats.

Format	Content	Examples
AN (1) AU CS CT (1) DED DN DT (TC) DUP ED EVAL (2) ISN JT (3) JTA (3) JTF (3) LA OS OT PD (3) PNO (1,2) PY (3) RE SO TI (1) TX (2) UP WC (1,2)	Accession Number Author Corporate Source Controlled Term (Drug Descriptors, Disease Descriptors, and Other Descriptors) ADIS Record Creation Date Document Number Document Type ADIS Last Update Date Entry Date Evaluation (Positive Features, Negative Features, Adis Comment, and Adis Evaluation) International Standard (Document) Number Journal Title, Full and Abbreviated Journal Title, Abbreviated Journal Title, Full Language Other Source Ongoing Trial Comment Publication Date Number of Patients Publication Year Reference Source Title Text (Global Study Outcome (Efficacy, Tolerability, Pharmacoeconomics), Study Message (Efficacy, Tolerability), Results Highlights (Efficacy, Tolerability), Purpose, Author Comments, Study Details (Design, Control, Phase, Methodology, EndPoints, Companies) Subject Details (Type, No., Age, Sex, Location, Disease, Characteristics), Drug, Drug Table (Drug/Treatment, Dose, Route, Frequency, Duration), Results (Results Table), Case Details (Toxicity, Dechallenge, Outcome, Claimed Association, Key Details), and Age Key) Update Date Word Count	D L4 1-4 AN D AU CS D CS 1,3-5 D CT 5-10 D DED D 1-3,7,8 DN D DT D DUP D ED D EVAL 1 5 D ISN D JT D JTA 2 D JTF D LA D OS OT D PD D PNO D PY D RE D SO D TI D TX D UP D WC
ALL BIB CBIB	AN, DN, TI, AU, CS, SO, DT, DED, DUP, RE, LA, WC, OS, ED, EVAL, TX, PNO, CT AN, DN, TI, AU, CS, SO, DT, DED, DUP, RE, LA, WC, OS, ED BIB in compressed format	D ALL D 2 L5 BIB D CBIB

DISPLAY and PRINT Formats (cont'd)

Format	Content	Examples
DALL IALL IBIB IND (1) SCAN (1,4) TEXT (2) TRIAL (TRI, SAM) (1)	ALL, delimited for post processing ALL, indented with text labels BIB, indented with text labels PNO, CT TI, PNO, CT (random display, no answer numbers) EVAL, TX, PNO TI, PNO, CT	D DALL D IALL D IBIB D IND D SCAN D TEXT D TRIAL TOTAL
HIT KWIC OCC (1)	Fields containing hit terms Hit terms with 20 words on either side (KeyWord-In-Context) Number of occurrences of hit terms and fields in which they occur	D HIT D KWIC NOH D OCC

(1) No online display fee for this format.

(2) This field is available only in the SUMMARY file segment.

(3) Custom display format only.

(4) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Accession Number	AN	Y	N
ADIS Last Record Update	DUP	Y	Y
ADIS Record Creation Date	DED	Y	Y
Author	AU	Y	Y
Citation	CIT	Y (2,3)	N
Controlled Term	CT	Y	N
Corporate Source	CS	Y	Y
Document Number	DN	Y	Y
Document Type	DT	Y	Y
Entry date	ED	Y	Y
Evaluation (4)	EVAL	Y	N
File Segment	FS	Y	Y
International Standard (Document) Number	ISN	Y	Y
Journal Title	JT	Y (5)	Y
Journal Title, Abbreviated	JTA	Y (6)	Y
Journal Title, Full	JTF	Y (6)	Y
Language	LA	Y	Y
Number of Patients (4)	PNO	Y	Y
Occurrence Count of Hit Terms	OCC	N	Y
Ongoing Trial Comment	OT	Y	N
Other Source	OS	Y	N

SELECT, ANALYZE, and SORT Fields (cont'd)

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Publication Date	PD	Y	Y
Publication Year	PY	Y	Y
Reference	RE	Y	Y
Text (4)	TX	Y (7)	N
Title	TI	Y (default)	Y
Treatment Code	TC	Y	Y
Update Date	UP	Y	Y
Word Count (4)	WC	N	Y

- (1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT CT.
- (2) SELECT HIT and ANALYZE HIT are not valid with this field.
- (3) Extracts first author, publication year, volume, and first page with a truncation symbol appended and with /RE appended to the terms created by SELECT.
- (4) This field is available only in the SUMMARY file segment.
- (5) Selects or analyzes full and abbreviated journal titles with /JT appended to the terms created by SELECT.
- (6) Appends /JT to the terms created by SELECT.
- (7) Appends /BI to the terms created by SELECT.

Full-Text Browsing

User Request	Example	System Response
DISPLAY BROWSE	=> DISPLAY BROWSE ENTER (L1) OR L#: ENTER (DIS), ANSWER NUMBERS, OR END:	NOVICE version
D BRO Answer number(s) Answer number(s) and format Format only Change default format Forward n fields Backward n fields Search forward for character string Search backward for character string End DISPLAY BROWSE	=> D BRO L1 : :1-3 :4 HIT :TI TX :*KWIC :F3 :B1 :S BONE MARROW :S- NAUSEA :END =>	EXPERT version display answers 1, 2, and 3 in default format display answer 4 in HIT format display title and text of last answer displayed change default to KWIC no answer displayed move forward 3 fields move backward 1 field search forward within record for 'bone marrow' search backward within record for 'nausea' exit DISPLAY BROWSE and return to => prompt

Sample Records

DISPLAY IALL

ACCESSION NUMBER: 2006:18471 ADISCTI
DOCUMENT NUMBER: 700009023
TITLE: ADIS TITLE: Effectiveness of an NK1 Antagonist in PTSD.
DOCUMENT TYPE: Ongoing Trial
ADIS REC. CREATED: 26 Nov 2005
ADIS LAST UPDATE: 4 Mar 2014
REFERENCE: Anxiety Disorders; Mental Disorders
1.) ClinicalTrials.gov: US National Institutes of Health
LANGUAGE: English
WORD COUNT: 283
OTHER SOURCE: ADISINSIGHT 1998005744
ENTRY DATE: Entered STN: 12 Jun 2006
Last Updated on STN: 7 Mar 2014
ONGOING TRIAL COMNT: Ongoing Trial Comment: This trial is entitled "Effectiveness of an NK1 Antagonist [vofopitant] in PTSD [post-traumatic stress disorder]". The primary outcome is the change in 17-item total severity Clinician Administered PTSD Scale.

TEXT - Subject Details:

Planned No: 47

No: 64

Location: USA

Disease: Post-traumatic-stress-disorders

Patient Inclusion: Aged 18-65 years; diagnosis of post-traumatic stress disorder for greater than or equal to 3 months; negative urine toxicology test; females willing to use an effective form of birth control throughout the study.

Patient Exclusion: Current diagnosis of schizophrenia or other psychotic disorder, current diagnosis of bipolar disorder or other psychiatric disorder except for depression secondary to post-traumatic stress disorder, participation in a clinical trial of a new drug during the previous 4 months or any other trial during the previous 3 months, current evidence or history of serious unstable medical illness or organic brain impairment, serious suicidal or homicidal risk, substance abuse within the last 90 days, use of effective psychiatric medications in the 2 weeks prior to screening or ***fluoxetine*** in last 5 weeks, consumption of more than 4 drinks/day per week if male or of more than 3 drinks/day per week if female, donation of blood within the previous month or intent to donate blood within one month of completing the study, previous treatment with an NK1 antagonist.

TEXT - Age Key: adult, elderly

TEXT - Study Details:

Status: completed

Actual Start: August 2005

Planned Finish: November 2008

Actual Finish: November 2008

Design: double-blind, parallel, prospective, randomised

Phase: II

Endpoints: Assessment scale scores

Biomarker levels (CSF levels of norepinephrine (NE) and NE metabolites.)

Brain volume (Hippocampal volume.)

clinical Global Impressions scale

Clinical response rate

Improvement in symptoms

Magnetic resonance imaging outcomes, Clinician Administered Post-Traumatic Stress Disorder Scale

Study Center: Baylor School of Medicine, Mount Sinai School of Medicine, Emory University, National Institute of Mental Health

Companies: GlaxoSmithKline

ADISCTI

ID: 700009023 (Clinical Trials Insight)
NCT00211861 (ClinicalTrials.gov: US National Institutes of Health)
U19MH069056()

NO. OF PATIENTS: 64

CONTROLLED TERM: Drug Descriptors: Vofopitant
CONTROLLED TERM: Disease Descriptors: Post traumatic stress disorders,
treatment

In North America

CAS
STN North America
P.O. Box 3012
Columbus, Ohio 43210-0012 U.S.A.

CAS Customer Center:
Phone: 800-753-4227 (North America)
614-447-3700 (worldwide)
Fax: 614-447-3751
Email: help@cas.org
Internet: www.cas.org

In Europe

FIZ Karlsruhe
STN Europe
P.O. Box 2465
76012 Karlsruhe
Germany
Phone: +49-7247-808-555
Fax: +49-7247-808-259
Email: helpdesk@fiz-karlsruhe.de
Internet: www.stn-international.com

In Japan

JAIICI (Japan Association for
International Chemical Information)
STN Japan
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021, Japan
Phone: +81-3-5978-3601 (Technical Service)
+81-3-5978-3621 (Customer Service)
Fax: +81-3-5978-3600
Email: support@jaici.or.jp (Technical Service)
customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp